Surgical ablation for atrial fibrillation: impact of Diabetes Mellitus type 2.
Atrial fibrillation
Diabetes mellitus type 2
Long-term follow-up
Surgical ablation
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
31 03 2023
31 03 2023
Historique:
received:
25
02
2023
accepted:
20
03
2023
medline:
4
4
2023
entrez:
2
4
2023
pubmed:
3
4
2023
Statut:
epublish
Résumé
Diabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surgery. The aim of this study was to evaluate the impact of DM type 2 on early and long-term outcomes of patients following surgical AF ablation. We performed an observational cohort study in Israel's largest tertiary care center. All data of patients who underwent surgical AF ablation, between 2006 and 2021 were extracted from our departmental database. Patients were divided into Group I (non-diabetic patients) and Group II (DM type 2 patients). We compared the two groups with respect to freedom from recurrent atrial arrhythmia, and mortality rate. The study population included 606 patients. Group I (non-DM patients), consisting of 484 patients, and Group II (DM type 2 patients), comprised 122 patients. Patients with DM were older, had more hypertension and incidence of cerebrovascular accident (CVA)/transient ischemic attack (TIA), higher EuroSCORE (p < .05 for all), and a longer bypass time-130 ± 40 vs. 122 ± 36 min (p = 0.028). The mean follow-up duration was 39.0 ± 22.7 months. Freedom from atrial fibrillation was similar between the non-DM and DM type 2 groups after a 1-year follow-up, 414 (88.2%) vs. 101 (87.1%) (p = 0.511), after a 3-year follow-up, 360 (86.3%) vs. 84 (79.9%) (p = 0.290) and after a 5-year follow-up, 226 (74.1%) vs. 55 (71.5%) (p = 0.622) respectively. Furthermore, 1- and 3-year mortality was similar between non-DM and DM type 2 groups, 2.5% vs. 4.9%, (p = 0.226) and 5.6% vs. 10.5% (p = 0.076) respectively. 5-year mortality was higher in Group II (DM type 2 patients) compared with Group I (non-DM patients), 11.1% vs. 23.4% (p = 0.009). Surgical ablation had a high success rate, with freedom from recurrent atrial arrhythmia at 1- 3- and 5- years follow-up in both the DM type 2 and non-DM groups. Furthermore,1- and 3-year mortality after surgical ablation was also similar in both groups. However, 5-year mortality was higher in the DM type 2 group.
Sections du résumé
BACKGROUND
Diabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surgery. The aim of this study was to evaluate the impact of DM type 2 on early and long-term outcomes of patients following surgical AF ablation.
METHODS
We performed an observational cohort study in Israel's largest tertiary care center. All data of patients who underwent surgical AF ablation, between 2006 and 2021 were extracted from our departmental database. Patients were divided into Group I (non-diabetic patients) and Group II (DM type 2 patients). We compared the two groups with respect to freedom from recurrent atrial arrhythmia, and mortality rate.
RESULTS
The study population included 606 patients. Group I (non-DM patients), consisting of 484 patients, and Group II (DM type 2 patients), comprised 122 patients. Patients with DM were older, had more hypertension and incidence of cerebrovascular accident (CVA)/transient ischemic attack (TIA), higher EuroSCORE (p < .05 for all), and a longer bypass time-130 ± 40 vs. 122 ± 36 min (p = 0.028). The mean follow-up duration was 39.0 ± 22.7 months. Freedom from atrial fibrillation was similar between the non-DM and DM type 2 groups after a 1-year follow-up, 414 (88.2%) vs. 101 (87.1%) (p = 0.511), after a 3-year follow-up, 360 (86.3%) vs. 84 (79.9%) (p = 0.290) and after a 5-year follow-up, 226 (74.1%) vs. 55 (71.5%) (p = 0.622) respectively. Furthermore, 1- and 3-year mortality was similar between non-DM and DM type 2 groups, 2.5% vs. 4.9%, (p = 0.226) and 5.6% vs. 10.5% (p = 0.076) respectively. 5-year mortality was higher in Group II (DM type 2 patients) compared with Group I (non-DM patients), 11.1% vs. 23.4% (p = 0.009).
CONCLUSION
Surgical ablation had a high success rate, with freedom from recurrent atrial arrhythmia at 1- 3- and 5- years follow-up in both the DM type 2 and non-DM groups. Furthermore,1- and 3-year mortality after surgical ablation was also similar in both groups. However, 5-year mortality was higher in the DM type 2 group.
Identifiants
pubmed: 37004023
doi: 10.1186/s12933-023-01810-x
pii: 10.1186/s12933-023-01810-x
pmc: PMC10067240
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
J Cardiothorac Vasc Anesth. 2020 Feb;34(2):401-408
pubmed: 31629606
Diabetes Care. 2016 Jan;39 Suppl 1:S13-22
pubmed: 26696675
Sci Rep. 2019 May 3;9(1):6890
pubmed: 31053744
Cardiovasc Diabetol. 2019 Mar 15;18(1):31
pubmed: 30876424
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Port J Card Thorac Vasc Surg. 2022 Jul 03;29(2):23-29
pubmed: 35780419
Cardiovasc Diabetol. 2022 Mar 14;21(1):39
pubmed: 35287684
JTCVS Tech. 2022 Dec 05;17:84-93
pubmed: 36820335
J Thorac Cardiovasc Surg. 2021 May;161(5):1816-1823.e1
pubmed: 31932056
Cardiovasc Diabetol. 2022 Jun 28;21(1):118
pubmed: 35765074
Eur J Cardiothorac Surg. 2017 Nov 1;52(5):888-894
pubmed: 28605469
Cardiovasc Diabetol. 2021 Jun 24;20(1):128
pubmed: 34167520
Am Heart J. 2015 Jan;169(1):175-84
pubmed: 25497264
Cardiovasc Diabetol. 2018 Nov 29;17(1):151
pubmed: 30497472
J Am Coll Cardiol. 2019 Aug 27;74(8):1107-1115
pubmed: 31439220
Expert Rev Cardiovasc Ther. 2022 Sep;20(9):707-717
pubmed: 35984314
Ann Thorac Surg. 2015 Dec;100(6):2262-9
pubmed: 26319487
Heart Rhythm O2. 2020 May 12;1(3):180-188
pubmed: 34113872
Br J Cardiol. 2022 Mar 08;29(1):8
pubmed: 35747310
Am J Cardiol. 2020 Mar 15;125(6):901-906
pubmed: 31973808
JAMA Cardiol. 2017 Mar 1;2(3):334-335
pubmed: 28196179
Ann Thorac Surg. 2009 Feb;87(2):663-9
pubmed: 19161815
Semin Thorac Cardiovasc Surg. 2019 Summer;31(2):141-145
pubmed: 30825589
J Thorac Cardiovasc Surg. 2019 Apr;157(4):1505-1514
pubmed: 30578060
Front Endocrinol (Lausanne). 2022 Aug 01;13:921159
pubmed: 35979438
Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):294-298
pubmed: 28964598
Eur J Cardiothorac Surg. 1999 Jul;16(1):9-13
pubmed: 10456395